Tex. Health & Safety Code § 491.059 · Subchapter B. DRUG DEVELOPMENT OF IBOGAINE TREATMENT
REPORTING REQUIREMENTS.
Text — Current through the 89th 2nd Called Legislative Session, 2025
(a) A consortium selected to conduct ibogaine drug development clinical trials shall quarterly prepare and submit to the commission:
(1) a report on the progress of the drug development clinical trials conducted under this subchapter; and
(2) a financial status report, including information to verify expenditures of state funds and required matching funds.
(b) The commission shall submit a report to the legislature on the progress of the drug development clinical trials conducted under this subchapter not later than December 1 of each year.
Notes and commentary — not statutory text
History
Added by Acts 2025, 89th Leg., R.S., Ch. 333 (S.B. 2308), Sec. 1, eff. June 11, 2025.
Source of truth
- Edition
- Current through the 89th 2nd Called Legislative Session, 2025
- Official file
- https://statutes.capitol.texas.gov/Docs/HS/htm/HS.491.htm
- Text hash
- sha256 2bc8266fe9606433269802c7868092733905932ff05fc90f3a9748c39890289e
- Composed by
- compose_tx.py 2026-10-05: the Legislative Council's chapter files read in document order; verify_tx.py's independent reading (lxml DOM walk) agrees character for character
Procedural information only. Not legal advice and not a substitute for the advice of an attorney. Confirm the current text with the official publisher before relying on it.